Now is the time to start thinking about your game plan for the 2027 JP Morgan Healthcare Conference. The strongest conference strategies begin long before attendees arrive in San Francisco. Early planning can help ensure your team stands out, engages key stakeholders, and makes the most of every opportunity. Interested in learning more about how Precision AQ can help elevate your presence at JPM 2027? Let's connect! #JPM2027 #JPMHC #Biotech #LifeSciences
Precision AQ - Investor Relations & External Communications
Public Relations and Communications Services
About us
Precision AQ - Investor Relations & External Communications (formerly Stern IR) is a premier investor relations firm, representing biotechnology companies across all market capitalizations and stages of development, and offering strategic and client-specific advisory services. For more information please visit our website at www.precisionaq.com
- Website
-
https://www.precisionaq.com/investor-relations
External link for Precision AQ - Investor Relations & External Communications
- Industry
- Public Relations and Communications Services
- Company size
- 11-50 employees
- Headquarters
- New York
- Type
- Privately Held
- Specialties
- Investor Relations, Healthcare, Pharmaceuticals and Biotechnology, and External Communications
Locations
-
Primary
Get directions
1270 Avenue of the Americas
New York, 10020, US
Employees at Precision AQ - Investor Relations & External Communications
Updates
-
The biotech market has recalibrated. Today's investors are rewarding companies that can clearly articulate not only how their science works, but why it matters, where it fits, and how it creates value. As capital markets continue to improve, companies that have invested in visibility, credibility, and investor relationships will be best positioned to capitalize on emerging opportunities. Our latest blog from Hannah Deresiewicz explores why investor relations should be viewed as a strategic function - not a transactional one activated ahead of a financing. Read more below. #InvestorRelations #Biotech #LifeSciences #CapitalMarkets #StrategicCommunications
The biotech market is moving again, but how do you ensure your company is prepared to navigate it? Read our latest blog to discover: ✔️ Ways to stand out in a crowded re-entry ✔️ The importance of engaging #InvestorRelations early ✔️ Positioning for capital in a recalibrated market 👉 Learn how Precision AQ's Investor Relations & External Communications team can help position your #Biotech company for success today: https://hubs.ly/Q04pwdp70
-
-
Congratulations to our client, Antares Therapeutics, on their new strategic collaboration with Novartis for the development and commercialization of first-in-class small molecule therapies targeted towards historically undruggable oncology targets. This partnership is a testament to the strength of Antares' discovery engine and will open the door to more opportunities to unlock high-value targets and deliver first-in-class precision medicines to patients with cancer and other serious diseases. #Biotech #Oncology #DrugDiscovery #PrecisionMedicine
Antares has entered into a strategic collaboration with Novartis to discover, develop and commercialize first-in-class small molecule therapies against historically undruggable oncology targets. This agreement underscores the strength and productivity of Antares’ discovery engine and enables us to scale that engine alongside Novartis’ world class development capabilities and global reach. Through this collaboration, we aim to translate our science into transformative therapies for patients, while continuing to advance our wholly owned and partnered portfolio, including our lead precision oncology program expected to enter the clinic in 2026. Visit https://bit.ly/4oP2npt to learn more. #Biotech #Oncology #DrugDiscovery #PrecisionMedicine
-
-
We were delighted to have Precision AQ client Nurix Therapeutics featured on BiotechTV live from #EHA2026, where Arthur T. Sands, M.D., Ph.D., CEO of Nurix, discussed newly presented data on bexobrutideg in chronic lymphocytic leukemia (CLL) and the company’s recently announced collaboration with Roche.
𝐄𝐇𝐀 𝟐𝟎𝟐𝟔: Nurix Therapeutics CEO Arthur T. Sands, M.D., Ph.D. discusses this week's big collaboration deal with Roche, and highlights the company's EHA data and broader platform. Full video: https://lnkd.in/ggJQUnbE He says he believes the Roche deal is an important transaction for the entire field of degraders. Plus, discussing antibody-degrader conjugates and an update on the company's immunology programs as well. BiotechTV is brought to you by: Mispro | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Genezen | Orchestra | Evaluate Ltd
-
Congratulations to client SynOx Therapeutics! Today's positive topline results from the Phase 3 TANGENT study marks a meaningful step forward for the TGCT community. Always encouraging to see late‑stage data that reflect both clinical efficacy and patient‑relevant outcomes—particularly with the potential to reduce long‑term treatment burden. 🔗 Read more: https://bit.ly/4c8gIsv
POSITIVE TOP LINE RESULTS FROM TANGENT STUDY IN TGCT Today, SynOx Therapeutics announced positive top-line results from the Phase 3 TANGENT study of emactuzumab — an important milestone for the company and, more importantly, for patients living with TGCT. https://lnkd.in/efa8jCWj For me personally, this moment brings a sense of perspective. When I joined as employee number one, we started with a dataset that showed promise, but required significant work to position it for a registrational study. What followed was a true team effort — building the organisation, strengthening the programme, and ultimately delivering a Phase 3 trial capable of generating meaningful data. What stands out most is what this could mean for patients. TGCT has long lacked sufficiently effective, well-tolerated treatment options, and the potential to deliver not only tumour control but real improvements in function and quality of life is what has driven the team throughout. This milestone reflects the scale of commitment behind it — from the team across every function, and from the investors who have supported SynOx with conviction throughout the journey. Their belief has enabled us to build, persist, and reach this point. These results are not a destination, but a transition — as we move toward regulatory engagement and prepare for the next phase of growth as an organisation. Proud of what the team has achieved — and focused on what comes next. Forbion HealthCap Bioqube VenturesGilde Healthcare Dirk Kersten Carl Kilander Jon Edwards Arthur Franken Philip Astley-Sparke Tom Heyman Chip Romp Carlo Incerti Audrey Cacaly Clement Salque Max Odlander Zosia van Eesteren #SynOx #TGCT #raredisease
-
-
Precision AQ - Investor Relations & External Communications reposted this
In this new biotech landscape, what used to work may not always be effective. The roles of IR and PR have evolved, yet too many organizations still operate on outdated assumptions. Let’s challenge the myths and get clear on what’s actually driving value in this environment. Learn more about how investor relations and external communications can help your company stand out: https://lnkd.in/epGk2P9h
-
Our Investor Relations team kicked off the spring investor conference circuit this week in Boston, the center of biotech innovation! From investor meetings at the TD Cowen 46th Annual Healthcare Conference to discussions on industry headwinds at our annual cocktail reception, our team had a productive week connecting with industry leaders and is encouraged about what 2026 will bring for the industry. Thank you to everyone who joined us. We look forward to continuing the dialogue in Miami next week as we help our partners shape the conversation across healthcare.
The Precision AQ Investor Relations team was onsite at the TD Cowen 46th Annual Healthcare Conference in Boston! It was another outstanding event from TD Cowen, and a great opportunity to connect with our Precision AQ clients, reconnect with former colleagues, meet new leaders across the industry, and engage with the broader biotech community. #PrecisionAQ #TDCowenHealthCare #HealthCare
-
-
Congratulations to Precision AQ IREC client 35Pharma on their proposed acquisition by GSK! This is a tremendous outcome for the entire team and will help accelerate the advancement of their pulmonary hypertension program as they look to offer a potentially transformative treatment option for this greatly underserved patient population.
We are excited to share that we have entered into an agreement with #GSK, under which GSK will acquire 35Pharma. The acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases. Read more: https://lnkd.in/enniNhGW
-
We’re thrilled to celebrate Hannah Deresiewicz for being honored by MM+M - Medical Marketing and Media in this year's 40 under 40 for her outstanding leadership and impact across the healthcare communications landscape! Those of us who are lucky to work with Hannah, we know just how powerfully she elevates corporate narratives. For every next‑generation biotech company she partners with, Hannah always brings her rich experience, unique perspective, and thoughtful guidance. Her ability to translate vision into meaningful action helps transform how biotech companies communicate and ultimately advance the science that matters! Beyond all that she does for some of the industry's biggest innovators, Hannah has been instrumental in cultivating a team and culture rooted in curiosity and storytelling, enabling our partners to thrive as they advance their pioneering therapies from the clinic into the hands of patients. Join us in celebrating Hannah with this incredible milestone!
We’re proud to celebrate Hannah Deresiewicz on being named to MM+M - Medical Marketing and Media's 2026 40 Under 40 — a recognition that reflects the impact she’s had across healthcare communications and strategy. As EVP and Managing Director of Precision AQ’s IREC team, Hannah has helped redefine how companies unify scientific, financial, and corporate narratives, especially in high‑stakes moments like IPOs, financings, and M&A. Her reflections on this honor highlight the clarity, discipline, and purpose she brings to the work, grounded in the principle of "tikkun olam" — a Jewish value centered on “repairing the world,” and a reminder that communication carries both strategic and moral responsibility. And yes — the night included a few surprise celebrity meet‑and‑greets, making an already special milestone even more memorable. Please join us in congratulating Hannah on this well‑earned recognition and celebrating the leadership she brings to our industry every day. Read more about the 2026 class of honorees here: https://hubs.ly/Q042YG0q0
-
-
J.P. Morgan may be over, but the momentum continues. Precision AQ’s IREC team didn’t just attend #JPM26, we helped shape conversations as both investor and strategic communications partners. Our dual vantage point helps us see value sooner and tell stories that resonate longer. Amid a packed, high‑energy week, one theme was clear: clear, value-based messaging and storytelling matters more than ever. If we didn’t get a chance to connect in San Francisco, we’re ready when you are.
-